Squarepoint’s NRX Pharmaceuticals NRXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-13,166
Closed -$53.8K – 4858
2026
Q2
$53.8K Buy
+13,166
New +$43.5K ﹤0.01% 4263
2025
Q3
– Sell
-42,202
Closed -$138K – 4781
2025
Q2
$138K Buy
+42,202
New +$106K ﹤0.01% 4082
2025
Q1
– Sell
-25,299
Closed -$55.7K – 5152
2024
Q4
$55.7K Buy
+25,299
New +$34K ﹤0.01% 4822
2022
Q1
– Sell
-2,950
Closed -$141K – 3307
2021
Q4
$141K Buy
+2,950
New +$213K ﹤0.01% 2833

Other funds holding NRXP

Squarepoint's NRXP Position: Q3 2026 in Review

Squarepoint sold out of NRX Pharmaceuticals (NRXP) in Q3 2026, closing a stake of 13,166 shares — an estimated $53.8K sold.

Squarepoint first reported a position in NRXP in Q4 2021 and held it in 4 quarters. The position peaked at $141K in Q4 2021. 50 funds tracked by Wall St. Rank hold NRXP as of Q3 2026.

  • Squarepoint reported no remaining NRX Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Squarepoint sold 13,166 NRX Pharmaceuticals shares in Q3 2026, an estimated $53.8K.
  • Squarepoint first reported a position in NRX Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Squarepoint's NRX Pharmaceuticals position peaked at $141K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.